Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma
Cellectis said that it has dosed the first patient in a phase 1 study – the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf CAR-T product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM). The French gene therapy company began the phase 1 dose-escalation study after getting clearance from the US Food […]